Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Congestive Heart Failure

Treatments: Drug: Placebo; Drug: Candesartan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00634712

SH-AHS-0007

D2454C00007

Details and patient eligibility

About

A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function

Enrollment: 734 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female aged 18 or above
• Congestive Heart Failure with symptoms for more than 4 weeks before starting study
• Provision of informed consent

Exclusion criteria

• Current low blood pressure with symptoms
• Liver disease considered significant by the study doctor
• Pregnant or lactating females

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

734 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Treatment:

Drug: Candesartan

2

Placebo Comparator group

Treatment:

Drug: Placebo